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Current treatments for Pseudomonas aeruginosa infections are becoming less effective
because of the increasing rates of multi-antibiotic resistance. Pharmacological targeting
of virulence through inhibition of quorum sensing (QS) dependent virulence gene
regulation has considerable therapeutic potential. In P. aeruginosa, the pqs QS
system regulates the production of multiple virulence factors as well as biofilm
maturation and is a promising approach for developing antimicrobial adjuvants for
combatting drug resistance. In this work, we report the hit optimisation for a series
of potent novel inhibitors of PqsR, a key regulator of the pqs system, bearing a
2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio) acetamide scaffold. The initial hit
compound 7 (PAO1-L IC50 0.98 ± 0.02µM, PA14 inactive at 10µM) was obtained
through a virtual screening campaign performed on the PqsR ligand binding domain
using the University of Nottingham Managed Chemical Compound Collection. Hit
optimisation gave compounds with enhanced potency against strains PAO1-L and
PA14, evaluated using P. aeruginosa pqs-based QS bioreporter assays. Compound 40
(PAO1-L IC50 0.25 ± 0.12µM, PA14 IC50 0.34 ± 0.03µM) is one of the most potent
PqsR antagonists reported showing significant inhibition of P. aeruginosa pyocyanin
production and pqs system signaling in both planktonic cultures and biofilms. The
co-crystal structure of 40 with the PqsR ligand binding domain revealed the specific
binding interactions occurring between inhibitor and this key regulatory protein.
Keywords:Pseudomonas aeruginosa, PqsR,MvfR, Pseudomonas quinolone signal (PQS), alkylquinolone, biofilms,
quorum sensing inhibition, quorum quenching
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INTRODUCTION
Pseudomonas aeruginosa is a Gram-negative pathogen able to
infect a range of human body sites causing serious tissue
damage, blood stream invasion, and systemic dissemination
(Strateva and Yordanov, 2009). This opportunistic pathogen
is particularly devastating for immuno-compromised patients
and a leading cause of death for those with cystic fibrosis
(Winstanley et al., 2016). Current treatments for P. aeruginosa
infections rely mainly on antibiotics inhibiting essential bacterial
targets required for survival. These therapies, whilst effective
in some cases, impose selective pressures leading to the rapid
emergence of resistance, particularly in biofilms (Blair et al.,
2015). There are ∼50,000 cases of P. aeruginosa infections in the
USA every year and around 13% are due to multidrug-resistant
strains (Ventola, 2015). Pseudomonas aeruginosa has developed
resistance to most antibiotic classes including aminoglycosides,
cephalosporins, fluoroquinolones and even carbapenems (Potron
et al., 2015). Therefore, there is an urgent need to develop
alternative strategies for effectively treating infections caused by
this organism. The pathogenicity of P. aeruginosa stems from
a wide range of secreted and cell-associated virulence factors
(Gellatly and Hancock, 2013). Anti-virulence strategies, through
the attenuation of virulence without interfering with bacterial
growth, are viewed as a promising alternative approach to combat
drug resistance since they exert less selective pressures on the
pathogen (Muhlen and Dersch, 2016; Fleitas Martinez et al.,
2019).
QS is a bacterial cell-to-cell communication mechanism
that allows bacteria to coordinate gene expression in response
to population density reflecting the local concentration of
extracellular signaling molecules termed autoinducers (AIs). P.
aeruginosa employs a quorum sensing (QS) network to regulate
the production of a wide range of virulence traits including
but not limited to, exoproducts such as pyocyanin, HCN,
elastase, lectinA, pyoverdine, drug efflux pumps, and factors
required for immune evasion (Williams and Camara, 2009). QS
also plays a key role in controlling biofilm development and
biofilm mediated resistance to antibiotics (Bjarnsholt et al., 2005;
Thomann et al., 2016; Maura and Rahme, 2017; Soukarieh et al.,
2018a). Pseudomonas aeruginosa has three highly interconnected
QS systems: two N-acylhomoserine lactone (AHL)-dependent
QS systems (the las and rhl systems) and the Pseudomonas
Quinolone Signal (pqs) system which relies on alkylquinolone
(AQ)-derived autoinducers (Lee and Zhang, 2015;Whiteley et al.,
2017).
The P. aeruginosa pqs system uses the LysR-type
transcriptional regulator PqsR (also known as MvfR),
to control the expression of the pqsABCDE operon that
encodes the enzymes required for the biosynthesis of 4-
hydroxy-2-heptylquinoline (HHQ) which, upon the action
of the mono-oxygenase PqsH, is converted to 2-heptyl-3-
hydroxy-4-quinolone (PQS). PQS and HHQ interact with
the C-terminal ligand binding domain of PqsR, resulting in a
conformational change that leads to the activation of the pqs
operon likely through the interaction of the helix-turn-helix
DNA binding domain of this protein with the pqsA promoter.
FIGURE 1 | Chemical structure of the M64 PqsR inhibitor.
This triggers the production virulence factors and secondary
metabolites through a range of PqsR-dependent and PqsR-
independent mechanisms, some of which involve PqsE (Diggle
et al., 2007; Ben Haj Khalifa et al., 2011; Rampioni et al.,
2016).
The pqs system is crucial for P. aeruginosa pathogenicity
and has been regarded as a promising therapeutic target to
alleviate antibiotic-resistant infections (Fleitas Martinez et al.,
2018). Several attempts to target the pqs system with various
PqsR inhibitors have previously been reported (Soukarieh et al.,
2018a,b). Of these inhibitors, M64 (Figure 1) was the first PqsR
inhibitor to show in vivo activity in a mouse lung infection
model (Starkey et al., 2014). Due to the lipophilic nature of the
PqsR ligand binding site, finding a new series of pqs inhibitors,
with improved drug-likeness remains a challenge (Ilangovan
et al., 2013). In this work, we report the synthesis and biological
evaluation of a new series of high potency PqsR inhibitors and
demonstrate their ability to inhibit QS in both planktonic and
biofilms cultures.
MATERIALS AND METHODS
Data Management and Analysis
Instant JChem was used for Structure Database Management,
Search and Prediction, Instant JChem 16.2.15.0 2016, ChemAxon
(http://www.chemaxon.com). Sigmoidal dose-response curves
and the representation of all data were prepared using
GraphPad Prism.
General Chemistry
Reagents and anhydrous solvents were purchased from Sigma
Aldrich, Alfa Aesar and Fisher Scientific, and were used without
further purification. Nuclear magnetic resonance: 1H-NMR and
13C-NMR, were obtained at room temperature using a Bruker
AV400 spectrometer operating at 400 MHz. The samples were
prepared in deuterated solvent: DMSO-d6 and CDCl3. Chemical
shifts (δ) were recorded in ppm and coupling constants (J) were
recorded in Hz. The spectra were analyzed using MestReNova
12.0.1 software. Mass spectrometry: Analytical HPLC were
performed on a Shimadzu UFLCXR system coupled to an
Applied Biosystems API2000. Three columns thermostated at
40◦C were used. Column one: Phenomenex Gemini-NX 3µm
C18, 50 × 2mm Column two: Phenomenex Luna 3µm (PFP2)
110A, 50× 2mm. Column three:Waters X terraMSC8 2.5m, 4.6
× 30mm. Flow rate 0.5 mL/min. UV detection at 220 (channel
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2) and 254 nm (channel 1). Short gradient: Pre-equilibration
run for one min at 5% B; then method run: 5–98% solvent B
in 2min, 98% B for 2min, 98–5% B in 0.5min then 5% for
1min. Long gradient: Pre-equilibration run for one min at 5%
B; then method run: 5% B for 0.5min, 10–98% solvent B in
8min, 98% B for 2min, 98–5% B in 0.5min then 5% B for 1min.
Solvent A: 0.1% Formic acid in water; solvent B: 0.1% Formic acid
in MeCN. Chromatography: Thin-layer chromatography (TLC)
was performed, UV light and standard TLC stains were used to
visualize the Merck Silica gel 60 Å F254 plates. Compounds were
purified via column chromatography using either a Thompson
pump or normal phase Interchim Puriflash pre-packed cartridges
consisting of 50µM silica, or a glass column using Merck
Geduran silica gel 60 Å (230–240µm) Column size selected was
generally 40–60 times the loading amount.
General Procedure A: Alkylation of Thiols
With tert-butyl 2-Bromoacetate (3–4)
tert-Butyl 2-bromoacetate (1 mmol) was added dropwise to a
suspension of 5-methyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiols
(1–2) (Sharma et al., 2014) (1 mmol) and triethylamine (1 mmol)
in anhydrous toluene (10mL) at 0◦C under N2. The reaction
mixture was allowed to slowly warm up to room temperature
and stirred for 3 h and was quenched with water (5mL) and
stirred at room temperature for further 5min. The mixture was
then diluted with water (30mL) and then extracted with EtOAc
(20mL× 3). The organic layers were combined and washed with
brine and dried over Na2SO4. The crude compound was purified
by column chromatography.
tert-Butyl 2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3
-yl)thio)acetate (3). The title compound was prepared from
5-methyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiol (1) (0.40 g,
1.83 mmol), tert-butyl 2-bromoacetate (0.280 g, 1.83 mmol)
and triethylamine (0.185 g, 1.83 mmol) according to general
procedure A. The crude product was purified by column
chromatography (petroleum ether/EtOAc 4:1) to give a white
solid (0.37 g, 62%). 1H NMR (400 MHz, DMSO-d6) δ 8.36 (d, J
= 7.6Hz, 1H), 7.79 (d, J = 4.1Hz, 2H), 7.51 (dq, J = 8.0, 4.3Hz,
1H), 4.10 (s, 2H), 3.83 (s, 3H), 1.42 (s, 9H). 13C NMR (101 MHz,
CDCl3) δ 168.04, 166.84, 146.28, 141.42, 141.14, 130.74, 122.90,
122.12, 118.01, 109.84, 82.07, 34.54, 28.03, 27.22. LCMS m/z calc
for C16H18N4O2S [M+H]+: 330.2, found 330.4 with tR 2.91min,
purity 95%.
tert-Butyl 2-((8-bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]
indol-3-yl)thio)acetate (4). The title compound was prepared
from 8-bromo-5-methyl-5H[1,2,4]triazino[5,6-b]indole-3-thiol
(2) (0.15 g, 0.53 mmol), tert-butyl 2-bromoacetate (0.081 g, 0.53
mmol) and triethylamine (0.53 g, 0.53 mmol) according to
general procedure A. The crude product was purified by column
chromatography (petroleum ether/EtOAc 4:1) to give a yellow
solid (0.20 g, 88%): 1H NMR (400 MHz, DMSO-d6) δ 8.52 (d,
J = 2.0Hz, 1H), 7.94 (dd, J = 8.7, 2.0Hz, 1H), 7.78 (d, J =
8.7Hz, 1H), 4.11 (s, 2H), 3.81 (s, 3H), 1.42 (s, 9H), 13CNMR (101
MHz, CDCl3) δ 167.92, 167.77, 146.62, 140.30, 140.13, 133.28,
125.09, 119.92, 116.10, 111.39, 82.22, 34.61, 28.02, 27.41. LCMS
m/z calc for C16H17BrN4O2S [M+H]+: 408.0, found 408.3 with
tR 3.05min, purity 95%.
General Procedure B: tert-butyl Ester
Deprotection (5–6)
Intermediates (3–4) were dissolved in DCM (3 mL/mmol), 4M
HCl in 1,4-dioxane (excess, 2 mL/mmol) was added to the
suspension. The mixture was then allowed to stir at room
temperature overnight. The solvent was removed under vacuum
to yield a light yellow solid. The crude product was washed with
diethyl ether and DCM and was used directly for next steps
without further purification.
2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)
acetic acid (5). The title compound was prepared from tert-butyl
2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetate
(3) (0.40 g, 1.21 mmol) according to general procedure B. The
product was obtained as a yellow solid (280mg, 84.34%). 1H
NMR (400 MHz, DMSO-d6) δ 8.34 (d, J = 7.7Hz, 1H), 7.79 (d, J
= 4.0Hz, 2H), 7.51 (dq, J = 8.1, 4.5Hz, 1H), 4.10 (s, 2H), 3.83 (s,
3H). 13C NMR (101 MHz, DMSO-d6) δ 170.50, 166.81, 146.54,
142.14, 131.47, 123.40, 121.92, 117.75, 111.70, 79.46, 33.58, 27.81.
LCMS m/z calc. for C12H10N4O2S [M+H]+: 274.4, found 274.3
with tR 2.40min, purity 95%.
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-
3-yl)thio)acetic acid (6). The title compound was prepared
from tert-butyl 2-((8-bromo-5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)acetate (4) (0.19 g, 0.46 mmol) according to
general procedure B. The product was obtained as a yellow solid
(0.13 g, 81.7%): 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, J =
2.0Hz, 1H), 7.94 (dd, J = 8.7, 2.0Hz, 1H), 7.78 (d, J = 8.7Hz,
1H), 4.14 (s, 2H), 3.81 (s, 3H). 13C NMR (101 MHz, DMSO-d6)
δ 168.10, 146.66, 140.93, 133.76, 124.20, 119.65, 115.51, 115.49,
113.88, 81.73, 34.30, 28.15. LCMS m/z calc for C12H9BrN4O2S
[M+H]+: 353.2, found 353.2 with tR 2.63min, purity 95%.
General Procedure C: HATU-Mediated
Amide Bond Formation (7–28)
Carboxylic acids (5–6) (1.0 eq), HATU (1.5 equiv.), DMAP
(0.10 equiv.) and various anilines (1.0 equiv.) were dissolved
in anhydrous NMP (0.1 mmol/ 3mL) and stirred at room
temperature for 5min before addition of DIPEA (6 equiv.). The
reaction mixture was allowed to stir at room temperature for
overnight. The reaction was monitored by TLC and quenched by
addition of water (20mL). The mixture was diluted with water
(10mL) and extracted with EtOAc (15 mL× 3) and the combined
organic layers were washed with Sat. NaHCO3 (20 mL× 3) and
brine (20mL) and dried over Na2SO4. Solvent was removed
under vacuum and the crude product was purified by column
chromatography to afford the target compounds.
N-(4-Chlorophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)acetamide (7). The title compound was
prepared from 2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetic acid (5) (0.050 g, 0.18 mmol) and 4-chloroaniline
(0.023 g, 0.18 mmol) according to general procedure C. The
crude product was purified by column chromatography
(petroleum ether/EtOAc 2:1) to give a white solid (0.022 g, 31%).
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1H NMR (400 MHz, DMSO-d6) δ 10.56 (s, 1H), 8.32 (d, J =
7.9Hz, 1H), 7.81–7.72 (m, 2H), 7.71–7.63 (m, 2H), 7.48 (td, J =
6.9, 5.9, 2.2Hz, 1H), 7.42–7.33 (m, 2H), 4.28 (s, 2H), 3.77 (s, 3H).
13CNMR (101MHz, DMSO-d6) δ 167.07, 166.92, 146.51, 142.05,
141.40, 138.50, 131.38, 129.19, 127.37, 123.32, 121.86, 121.11,
117.71, 111.62, 35.99, 27.72. LCMS m/z calc.for C18H14ClN5OS
[M+H]+: 383.3, found 383.9 with tR 2.84min, purity 95%.
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-
3-yl)thio)-N-(4-chlorophenyl)acetamide (8). The title
compound was prepared from 2-((8-bromo-5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (6) (0.050 g,
0.1415 mmol) and 4-chloroaniline (0.020 g, 0.1562 mmol)
according to general procedure C. The crude product was
purified by column chromatography (petroleum ether/EtOAc
2:1) to give a white solid (0.010 g, 15%). 1H NMR (400 MHz,
DMSO-d6) δ 10.57 (s, 1H), 8.50 (d, J = 2.0Hz, 1H), 7.93 (dd, J
= 8.7, 2.0Hz, 1H), 7.76 (d, J = 8.7Hz, 1H), 7.72–7.60 (m, 2H),
7.42–7.34 (m, 2H), 4.28 (s, 1H), 3.77 (s, 1H). 13C NMR (101
MHz, DMSO-d6) δ 167.86, 166.82, 146.71, 140.96, 140.55, 138.49,
133.71, 129.20, 127.38, 124.18, 121.11, 119.71, 115.45, 113.86,
36.01, 27.90. LCMS m/z calc. for C18H14BrClN5OS [M+H]+:
462.3, found 462.7 with tR 2.91min, purity 95%.
2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-
phenylacetamide (9). The title compound was prepared from
2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic
acid (5) (0.050 g, 0.18 mmol) and aniline (0.017 g, 0.18 mmol)
according to general procedure C. The crude product was
purified by column chromatography (petroleum ether/EtOAc
2:1) to give a white solid (0.013 g, 20%). 1H NMR (400 MHz,
DMSO-d6) δ 10.42 (s, 1H), 8.33 (d, J = 7.8Hz, 1H), 7.81–7.72
(m, 2H), 7.66–7.58 (m, 2H), 7.49 (ddd, J = 8.1, 5.2, 3.0Hz,
1H), 7.32 (t, J = 7.9Hz, 2H), 7.11–7.02 (m, 1H), 4.28 (s, 2H),
3.79 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 167.17, 166.70,
146.54, 142.07, 141.40, 139.56, 131.39, 129.27, 123.83, 123.34,
121.88, 119.57, 117.74, 111.65, 36.01, 27.75. LCMS m/z calc for
C18H15N5OS [M+H]+: 349.4, found 349.4 with tR 2.72min,
purity 95%.
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)-N-phenylacetamide (10). The title compound was
prepared from 2-((8-bromo-5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)acetic acid (6) (0.050 g, 0.14 mmol) and
aniline (0.013 g, 0.14 mmol) according to general procedure C.
The crude product was purified by column chromatography
(petroleum ether/EtOAc 2:1) to give a white solid (0.015 g, 25%).
1H NMR (400 MHz, DMSO-d6) δ 10.42 (s, 1H), 8.49 (d, J =
1.9Hz, 1H), 7.93 (dd, J = 8.7, 2.0Hz, 1H), 7.76 (d, J = 8.7Hz,
1H), 7.62 (d, J = 7.9Hz, 2H), 7.32 (t, J = 7.9Hz, 2H), 7.06 (t, J
= 7.4Hz, 1H), 4.29 (s, 2H), 3.78 (s, 3H). 13C NMR (101 MHz,
DMSO-d6) δ 167.96, 166.60, 146.71, 140.94, 140.52, 139.54,
133.69, 132.07, 129.27, 129.14, 124.16, 123.84, 119.71, 119.57,
115.44, 113.85, 36.03, 27.91. LCMS m/z calc. for C18H14BrN5OS
[M+H]+: 429.2, found 428.3 with tR 2.87min, purity 95%.
N-(3-Chlorophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)acetamide (11). The title compound was
prepared from 2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)
thio)acetic acid (5) (0.040 g, 0.15 mmol) and 3-chloroaniline
(0.019 g, 0.15 mmol) according to general procedure C. The
crude product was purified by column chromatography
(petroleum ether/EtOAc 2:1) to give white solid (0.013 g, 23%).
1H NMR (400 MHz, DMSO-d6) δ 10.62 (s, 1H), 8.34 (d, J =
7.8Hz, 1H), 7.84 (t, J = 2.0Hz, 1H), 7.78 (d, J = 3.9Hz, 2H),
7.54–7.28 (m, 2H), 7.36 (t, J = 8.1Hz, 1H), 7.18–7.05 (m, 1H),
4.29 (s, 2H), 3.78 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ
167.19, 167.01, 146.55, 142.11, 141.46, 140.98, 133.60, 131.42,
131.02, 123.56, 123.35, 121.91, 119.00, 117.94, 117.74, 111.67,
36.01, 27.74. LCMSm/z calc.for C15H14ClN5OS [M+H]+: 383.8,
found 383.9 with tR 2.87min, purity 95%.
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-
3-yl)thio)-N-(3-chlorophenyl)acetamide (12). The title
compound was prepared from 2-((8-bromo-5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (6) (0.050 g, 0.14
mmol) and 3-chloroaniline (0.018 g, 0.14 mmol) according to
general procedure C. The crude product was purified by column
chromatography (petroleum ether/EtOAc 2:1) to give a white
solid (0.010 g, 15.4%). 1H NMR (400 MHz, DMSO-d6) δ 10.63
(s, 1H), 8.50 (d, J = 1.9Hz, 1H), 7.93 (dd, J = 8.7, 2.0Hz, 1H),
7.84 (t, J = 2.1Hz, 1H), 7.76 (d, J = 8.6Hz, 1H), 7.52–7.45 (m,
1H), 7.35 (d, J = 8.1Hz, 1H), 7.16–7.07 (m, 1H), 4.29 (s, 2H),
3.77 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 167.79, 167.09,
146.71, 140.96, 140.58, 133.71, 133.60, 131.02, 124.17, 123.57,
119.69, 119.00, 117.94, 115.45, 113.86, 36.03, 27.90. LCMS m/z
calc. for C18H14BrClN5OS [M+H]+: 464.2, found 464.3 with tR
2.98min, purity 95%.
N-(3,4-Dichlorophenyl)-2-((5-methyl-5H-[1,2,4]triazino
[5,6-b]indol-3-yl)thio)acetamide (13). The title compound
was prepared from 2-((5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)acetic acid (5) (0.070 g, 0.25 mmol) and
3,4-dichloroaniline (0.041 g, 0.25 mmol) according to general
procedure C. The crude product was purified by column
chromatography (petroleum ether/EtOAc 2:1) to give a white
solid (0.005 g, 5%). 1H NMR (400 MHz, DMSO-d6) δ 10.73 (s,
1H), 8.33 (d, J = 7.8Hz, 1H), 8.02 (d, J = 2.4Hz, 1H), 7.84–7.74
(m, 2H), 7.60 (d, J = 8.8Hz, 1H), 7.56–7.28 (m, 2H), 4.29 (s,
2H), 3.78 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 167.37,
166.94, 146.55, 142.12, 141.48, 139.62, 131.53, 131.44, 131.28,
125.26, 123.37, 121.91, 120.72, 119.61, 117.74, 111.69, 36.00,
27.75. LCMS m/z calc.for C18H13Cl2N5OS [M+H]+: 418.3,
found 418.2 with tR 2.95min, purity 95%.
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3
-yl)thio)-N-(3,4-dichlorophenyl)acetamide (14). The title
compound was prepared from 2-((8-bromo-5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (6) (0.070 g, 0. 20
mmol) and 3,4-dichloroaniline (0.035 g, 0.21 mmol) according to
general procedure C. The crude product was purified by column
chromatography (petroleum ether/EtOAc 2:1) to give white solid
(0.005 g, 5%). 1H NMR (400 MHz, DMSO-d6) δ 10.73 (d, J =
7.6Hz, 1H), 8.50 (d, J = 1.9Hz, 1H), 8.02 (d, J = 2.3Hz, 1H),
7.94 (dd, J = 8.7, 1.9Hz, 1H), 7.76 (d, J = 8.7Hz, 1H), 7.60 (d, J
= 8.8Hz, 1H), 7.53 (dd, J = 8.9, 2.4Hz, 1H), 4.29 (s, 2H), 3.76 (s,
3H). 13C NMR (101 MHz, DMSO-d6) δ 167.37, 166.94, 146.55,
142.12, 141.48, 139.62, 131.53, 131.44, 131.28, 125.26, 123.37,
121.91, 120.72, 119.61, 117.74, 111.69, 36.00, 27.75. LCMS m/z
calc. for C18H12BrCl2N5OS [M+H]+: 497.2, found 497.19 with
tR 3.06min, purity 95%.
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N-(4-Fluorophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)acetamide (15). The title compound was
prepared from 2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetic acid (5) (0.070 g, 0.26 mmol) and 4-fluoroaniline
(0.028 g, 0.26 mmol) according to general procedure C. The
crude product was purified by column chromatography
(petroleum ether/EtOAc 2:1) to give a white solid (0.030 g, 32%).
1H NMR (400 MHz, DMSO-d6) δ 10.48 (s, 1H), 8.33 (d, J =
7.8Hz, 1H), 7.86–7.71 (m, 2H), 7.69–7.59 (m, 2H), 7.49 (ddd, J =
8.0, 5.3, 2.9Hz, 1H), 7.16 (t, J = 8.9Hz, 2H), 4.27 (s, 2H), 3.78 (s,
3H). 13C NMR (101 MHz, DMSO-d6) δ 167.12, 166.64, 146.54,
142.08, 141.41, 135.96, 131.40, 123.34, 121.88, 121.38, 121.30,
117.74, 115.96, 115.74, 111.65, 35.91, 27.74. LCMS m/z calc.for
C18H14FN5OS [M+H]+: 367.1, found 367.4 with tR 2.75min,
purity 95%.
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-
3-yl)thio)-N-(4-fluorophenyl)acetamide (16). The title
compound was prepared from 2-((8-bromo-5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (6) (0.070 g, 0.20
mmol) and 4-fluoroaniline (0.022 g, 0.20 mmol) according to
general procedure C. The crude product was purified by column
chromatography (petroleum ether/EtOAc 2:1) to give a white
solid (0.027 g, 30%): 1H NMR (400 MHz, DMSO-d6) δ 10.48
(s, 1H), 8.49 (d, J = 2.0Hz, 1H), 7.92 (dd, J = 8.7, 2.0Hz, 1H),
7.75 (d, J = 8.7Hz, 1H), 7.68–7.57 (m, 2H), 7.16 (t, J = 8.9Hz,
2H), 4.27 (s, 2H), 3.77 (s, 3H). 13C NMR (101 MHz, DMSO-d6)
δ 167.91, 166.55, 146.71, 140.95, 140.54, 135.92, 133.70, 124.17,
121.38, 121.30, 119.70, 115.96, 115.74, 115.45, 113.85, 35.93,
27.90. LCMS m/z calc. for C18H13BrFN5OS [M+H]+: 446.3,
found 446.3 with tR 2.88min, purity 95%.
2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-
(p-tolyl)acetamide (17). The title compound was prepared from
2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic
acid (5) (0.070 g, 0.26 mmol) and 4-methylaniline (0.027 g, 0.26
mmol) according to general procedure C. The crude product was
purified by column chromatography (petroleum ether/EtOAc
2:1) to give a white solid (0.032 g, 35%). 1H NMR (400 MHz,
DMSO-d6) δ 10.33 (s, 1H), 8.29 (d, J = 7.8Hz, 1H), 7.74 (d, J =
6.8Hz, 2H), 7.49 (dd, J = 17.2, 7.7Hz, 3H), 7.12 (d, J = 8.0Hz,
2H), 4.26 (s, 2H), 3.76 (s, 3H), 2.25 (s, 3H). 13C NMR (101 MHz,
DMSO-d6) δ 167.19, 166.28, 146.48, 142.00, 141.33, 137.06,
132.74, 131.33, 129.63, 123.29, 121.82, 119.58, 117.70, 111.57,
35.98, 27.72, 20.91. LCMS m/z calc. for C19H17N5OS [M+H]+:
363.4, found 363.4 with tR 2.78min, purity 95%.
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)-N-(p-tolyl)acetamide (18). The title compound was
prepared from 2-((8-bromo-5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)acetic acid (6) (0.070 g, 0.20 mmol) and
4-methylaniline (0.030 g, 0.20 mmol) according to general
procedure C. The crude product was purified by column
chromatography (petroleum ether/EtOAc 2:1) to give a white
solid (0.015 g, 12 %). 1H NMR (400 MHz, DMSO-d6) δ 10.34
(s, 1H), 8.47 (d, J = 2.0Hz, 1H), 7.91 (dd, J = 8.7, 2.0Hz, 1H),
7.74 (d, J = 8.7Hz, 1H), 7.51 (d, J = 8.4Hz, 2H), 7.12 (d, J =
8.1Hz, 2H), 4.27 (s, 2H), 3.77 (s, 3H), 2.25 (s, 3H). 13C NMR
(101 MHz, DMSO-d6) δ 168.00, 166.33, 146.69, 140.91, 140.49,
137.05, 133.67, 132.74, 129.63, 124.14, 119.70, 119.58, 115.44,
113.84, 36.00, 27.91, 20.92. LCMS m/z calc. for C19H16BrN5OS
[M+H]+: 442.3, found 442.1 with tR 2.95min, purity 95%.
N-(4-Methoxyphenyl)-2-((5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetamide (19). The
title compound was prepared from 2-((5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (5) (0.070 g,
0.26 mmol) and 4-methoxy aniline (0.031 g, 0.26 mmol)
according to general procedure C. The product was obtained as
a yellow solid (0.095 g, 98%). 1H NMR (400 MHz, DMSO-d6) δ
10.27 (s, 1H, H-7), 8.32 (d, J = 7.7Hz, 1H), 7.88–7.70 (m, 2H),
7.56–7.51 (m, 2H), 7.48 (ddd, J = 2.6, 5.6, 8.1Hz, 1H), 6.96–6.71
(m, 2H), 4.25 (s, 2H, H-6), 3.79 (s, 3H), 3.72 (s, 3H). 13C NMR
(101 MHz, DMSO-d6) δ 167.20, 166.15, 155.75, 146.45, 142.06,
141.37, 132.70, 131.38, 123.33, 121.86, 121.13, 117.75, 114.37,
111.64, 38.71, 35.88, 27.74. LCMS m/z calc for C19H17N5O2S+
[M+H]+: 380.4, found 379.4 with tR 2.70min, purity 95%.
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol
-3-yl)thio)-N-(4-methoxyphenyl)acetamide (20). The title
compound was prepared from 2-((8-bromo-5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (6) (0.070 g, 0.20
mmol) and 4-methoxyaniline (0.023 g, 0.20 mmol) according to
general procedure C. The crude product was purified by column
chromatography (petroleum ether/EtOAc 2:1) to give a light
yellow solid (0.017 g, 18%). 1H NMR (400 MHz, DMSO-d6) δ
10.28 (s, 1H), 8.49 (d, J = 2.0Hz, 1H), 7.93 (dd, J = 8.7, 2.0Hz,
1H), 7.76 (d, J = 8.7Hz, 1H), 7.56–7.49 (m, 2H), 6.93–6.85
(m, 2H), 4.25 (s, 2H, H5), 3.78 (s, 3H), 3.72 (s, 3H). 13C NMR
(101 MHz, DMSO-d6) δ 168.03, 166.05, 155.76, 146.72, 140.94,
140.50, 133.68, 132.69, 124.15, 121.13, 119.72, 115.44, 114.38,
113.85, 38.72, 35.90, 27.92. LCMS m/z calc. for C19H17BrN5O2S
[M+H]+: 458.3, found 458.3 with tR 2.87min, purity 95%.
2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)
-N-(4(trifluoromethoxy)phenyl)acetamide (21). The
title compound was prepared from 2-((5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (5) (0.050 g,
0.18 mmol) and 4-trifluoromethoxyaniline (0.032 g, 0.18 mmol)
according to general procedure C. The crude product was
purified by column chromatography (petroleum ether/EtOAc
2:1) to give a white solid (0.005 g, 6%). 1H NMR (400 MHz,
DMSO-d6) δ 10.63 (s, 1H), 8.33 (d, J = 7.9Hz, 1H), 7.84–7.62
(m, 4H), 7.49 (ddd, J = 8.1, 5.3, 2.8Hz, 1H), 7.34 (d, J = 8.6Hz,
2H), 4.29 (s, 2H), 3.78 (d, J = 1.7Hz, 3H). 13C NMR (101 MHz,
DMSO-d6) δ 178.30, 167.05, 167.00, 146.55, 142.10, 141.44,
138.74, 131.41, 123.35, 122.18, 121.90, 120.92, 117.74, 111.66,
35.95, 27.75. LCMS m/z calc. for C19H14F3N5O2S [M+H]+:
283.4, found 283.4 with tR 2.91min, purity 95%.
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol
-3-yl)thio)-N-(4- (trifluoromethoxy)phenyl)acetamide (22).
The title compound was prepared from 2-((8-bromo-5-methyl-
5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (6) (0.050 g,
0.14 mmol) and 4-trifluoromethoxyaniline (0.021mL, 0.16
mmol) according to general procedure C. The crude product was
purified by column chromatography (petroleum ether/EtOAc
2:1) to give a white solid (0.007 g, 9%). 1H NMR (400 MHz,
DMSO-d6) δ 10.63 (s, 1H), 8.48 (d, J = 2.0Hz, 1H), 7.92 (dd, J =
8.7, 2.0Hz, 1H), 7.83–7.64 (m, 3H), 7.34 (d, J = 8.6Hz, 2H), 4.29
(s, 2H), 3.77 (d, J = 5.3Hz, 3H). 13CNMR (101MHz, DMSO-d6)
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δ 167.83, 167.00, 166.91, 146.70, 142.09, 140.95, 140.56, 138.73,
133.70, 124.16, 122.18, 120.93, 119.69, 119.33, 115.45, 113.85,
111.66, 35.97, 27.74. LCMS m/z calc. for C19H13BrF3N5O2S
[M+H]+: 512.1, found 512.3 with tR 3.05min, purity 95%.
N-(4-(Cyanomethyl)phenyl)-2-((5-methyl-5H-[1,2,4]
triazino[5,6-b]indol-3-yl)thio)acetamide (23). The
title compound was prepared from 2-((5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (5) (0.080 g,
0.0.29 mmol) and 2-(4-aminophenyl)acetonitrile (0.028 g, 0.32
mmol) according to general procedure C. The crude product was
purified by column chromatography (petroleum ether/EtOAc
2:1) to give a white solid (58.9mg, 52%). 1H NMR (400 MHz,
DMSO-d6) δ 10.52 (d, J = 10.1Hz, 1H), 8.29 (d, J = 7.7Hz, 1H),
7.95 (s, 1H), 7.78–7.68 (m, 2H), 7.67–7.60 (m, H), 7.46 (ddd, J =
1.8, 6.5, 8.0Hz, 1H), 7.30 (d, J = 8.3Hz, 2H), 4.27 (s, 2H), 3.97
(s, 2H), 3.76 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 167.12,
166.85, 146.49, 142.01, 141.34, 138.94, 131.39, 129.04, 126.39,
123.33, 121.84, 120.00, 119.81, 117.67, 111.58, 35.96, 27.70, 22.30.
LCMS m/z calc. for C20H17N6OS [M+H]+: 389.4, found 389.3
with tR 2.66min, purity> 95%.
2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-
(4-phenoxyphenyl)acetamide (24). The title compound was
prepared from 2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetic acid (5) (0.10 g, 0.36 mmol) and 4-phenoxyaniline
(0.067 g, 0.36 mmol) according to general procedure C. The
crude product was purified by column chromatography
(petroleum ether/EtOAc 2:1) to give a white solid (0.094 g,
58%). 1H NMR (400 MHz, DMSO-d6) δ 10.45 (s, 1H), 8.35–8.27
(m, 1H), 7.82–7.71 (m, 2H), 7.70–7.60 (m, 2H), 7.48 (ddd,
J = 8.1, 5.6, 2.6Hz, 1H), 7.40–7.31 (m, 2H), 7.13–7.05 (m,
1H), 7.04–6.92 (m, 4H), 4.28 (s, 2H), 3.79 (s, 3H). 13C NMR
(101 MHz, DMSO-d6) δ 174.23, 166.53, 142.06, 141.39, 135.47,
131.38, 130.28, 123.46, 123.32, 121.86, 121.29, 119.98, 118.34,
117.74, 111.63, 35.93, 27.75. LCMS m/z calc. for C24H19N5O2S
[M+H]+: 441.5, found 441.5 with tR 2.95min, purity 95%.
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3
-yl)thio)-N-(4-phenoxyphenyl)acetamide (25). The title
compound was prepared from 2-((8-bromo-5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (6) (0.10 g, 0.28
mmol) and 4-phenoxy aniline (0.052 g, 0.28 mmol) according to
general procedure C. The crude product was purified by column
chromatography (petroleum ether/EtOAc 2:1) to give a white
solid (0.027 g, 18%). 1H NMR (400 MHz, DMSO-d6) δ 10.46
(s, 1H), 8.47 (d, J = 2.0Hz, 1H), 7.91 (dd, J = 8.7, 2.0Hz, 1H),
7.74 (d, J = 8.7Hz, 1H), 7.68–7.58 (m, 2H), 7.42–7.29 (m, 2H),
7.13–7.07 (m, 1H), 7.05–6.90 (m, 4H), 4.28 (s, 2H), 3.78 (s, 3H).
13CNMR (101MHz, DMSO-d6) δ 166.28, 157.78, 152.30, 146.68,
140.92, 140.51, 135.45, 133.67, 130.28, 124.13, 123.47, 121.29,
119.97, 119.68, 118.35, 115.44, 113.83, 35.96, 27.92 LCMS m/z
calc. for C24H18BrN5O2S+ [M+H]+: 520.4, found 520.4 with tR
3.06min, purity 95%.
N-(4-Bromophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)acetamide (26). The title compound was
prepared from 2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetic acid (5) (0.070 g, 0.26 mmol) and 4-bromoaniline
(0.044 g, 0.26 mmol) according to general procedure C. The
crude product was purified by column chromatography
(petroleum ether/EtOAc 2:1) to give a white solid (0.030 g, 27%).
1H NMR (400 MHz, DMSO-d6) δ 10.56 (s, 1H), 8.33 (d, J =
7.7Hz, 1H), 7.89–7.72 (m, 2H), 7.69–7.57 (m, 2H), 7.55–7.28 (m,
3H), 4.28 (s, 2H), 3.77 (s, 3H). 13C NMR (101 MHz, DMSO-d6)
δ 167.08, 166.94, 146.55, 142.10, 141.28, 138.92, 132.11, 131.42,
123.36, 121.90, 121.50, 117.75, 115.40, 111.68, 36.01, 27.75.
LCMS m/z calc. for C18H14BrN5OS [M+H]+: 428.3, found
428.3 with tR 2.87min, purity 95%.
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-
3-yl)thio)-N-(4-bromophenyl)acetamide (27). The title
compound was prepared from 2-((8-bromo-5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (6) (0.070 g, 0.20
mmol) and 4-bromoaniline (0.034 g, 0.20 mmol) according to
general procedure C. The crude product was purified by column
chromatography (petroleum ether/EtOAc 2:1) to give a yellow
solid (0.007 g, 7%). 1H NMR (400 MHz, DMSO-d6) δ 10.57 (s,
1H), 8.49 (d, J = 2.0Hz, 1H), 7.93 (dd, J = 8.7, 2.1Hz, 1H), 7.76
(d, J = 8.7Hz, 1H), 7.64–7.56 (m, 2H), 7.55–7.44 (m, 2H), 4.28
(s, 2H), 3.76 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 167.08,
166.95, 146.55, 142.10, 141.44, 138.92, 132.11, 131.42, 123.36,
121.91, 121.50, 117.75, 115.39, 111.68, 36.01, 27.75. LCMS m/z




(pyrimidin-2-yloxy)aniline (0.065 g, 0.238 mmol), 2-((5-
methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (5)
(0.064 g, 0.238 mmol), HATU (0.135 g, 0.357 mmol), DIPEA
(0.165mL, 0.952 mmol), and DMAP (0.030 g, 0.0238 mmol)
were dissolved in NMP (2mL). The reactionmixture was allowed
to stir at room temperature overnight and monitored by TLC.
The crude product was purified by column chromatography
(petroleum ether/EtOAc 1:1) to give a white solid (31mg, 29%).
1H NMR (400 MHz, DMSO-d6) δ 10.50 (s, 1H), 8.63 (d, J =
4.8Hz, 2H), 8.31 (d, J = 7.8Hz, 1H), 7.75 (d, J = 5.2Hz, 2H),
7.67 (d, J = 8.5Hz, 2H), 7.47 (ddd, J = 2.6, 5.8, 8.2Hz, 1H),
7.25 (t, J = 4.8Hz, 1H), 7.16 (d, J = 8.4Hz, 2H), 4.30 (s, 2H),
3.79 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 167.13, 166.67,
165.37, 160.47, 148.77, 146.53, 142.06, 141.40, 136.67, 131.38,
123.32, 122.46, 121.88, 120.83, 117.73, 117.30, 111.61, 35.96,
27.76. LCMS m/z calc. for C22H18N7O2S+ [M+H]+: 444.5,
found 444.3 with tR 2.62min, purity>95%.
General Procedure D: Acylation of Anilines
to Form Bromoacetatamides (32–37)
Aniline, 4-chloroaniline or 4-chloro-N-methylaniline and Et3N
(2 equiv.) were dissolved in anhydrous DCM at 0◦C under N2
protection followed by addition of various bromoacetyl chlorides
(29–31) (1.0 equiv.). The reaction mixture was allowed to slowly
warm up to room temperature and stirred for 4 h with monitored
by TLC. Once the reaction was complete, solvent was removed
under vacuum and crude product was used directly for next step
without further purification (Deora et al., 2019).
2-Bromo-N-(4-(pyridin-2-yloxy)phenyl)acetamide (33).
The title compound was prepared according to general
procedures B from 4-(Pyridin-2-yloxy) aniline (100mg, 32.57
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mmol), Et3N (3 equiv.) and 2-bromoacetyl chloride (29)
(1.1 equiv.). The crude product was purified by column
chromatography (petroleum ether/EtOAc 5:1) to give a solid
(71mg, 47%). 1H NMR (400 MHz, CDCl3) δ 8.19 (dd, J = 2.0,
5.1Hz, 1H), 7.64 (ddd, J = 2.0, 7.1, 8.2Hz, 1H), 6.99–6.90 (m,
3H), 6.83 (dd, J = 1.0, 8.3Hz, 1H), 6.76–6.67 (m, 2H), 3.65 (s,
2H). 13C NMR (101 MHz, CDCl3) δ 164.54, 147.74, 146.04,
143.50, 139.19, 122.29, 117.88, 116.14, 110.78, 45.81. LCMS m/z
calc. for C13H11BrN2O2 [M+H]+: 307.1, found 307.0 with tR
2.59min, purity> 95%.
2-Bromo-N-(4-chlorophenyl)acetamide (37). The title
compound was prepared from 2-bromopropanoyl chloride (30)
(0.10 g, 0.71 mmol) and 4-chloro-N-methylaniline (0.12 g, 0.71
mmol) according to general procedure D. The crude product was
purified by column chromatography (petroleum ether/EtOAc
6:1) to give a white solid (149mg, 76%). 1H NMR (400 MHz,
CDCl3) δ 7.44 (d, J = 8.3Hz, 2H), 7.26 (d, J = 8.2Hz, 2H),
4.24 (q, J = 6.6Hz, 1H), 3.28 (s, 3H), 1.74 (d, J = 6.7Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 169.47, 141.35, 134.42, 130.22,
128.64, 38.78, 38.13, 21.74. LCMS m/z calc. for C8H8BrClNO
[M+H]+: 249.5, found 250.0 with tR 2.63min, purity> 95%.
General Procedure E: Alkylation of Thiols
(1–2) With Bromoacetamides (32–37) to
Give Thioethers (38–44)
The substituted 5-methyl-5H-[1,2,4]triazino[5,6-b]indole-3-
thiol intermediates 1–2 (1 equiv.) and Et3N (2 equiv.) were
dissolved in anhydrous DCM (0.1 mmol/5mL) followed by
addition of bromoacetamides (32–37) (1.0 equiv.) at 0◦C under
N2. The reaction mixture was allowed slowly warm up to room
temperature and stir for 4 h. The reaction was monitored by TLC.
Once the reaction finished, solvent was removed under vacuum.
The crude product was purified by column chromatography.
N-(2-Chlorophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)acetamide (38). The title compound was
prepared from 2-bromo-N-(2-chlorophenyl)acetamide (32)
(Sun et al., 2014) (0.1 g, 0.41 mmol) and 5-methyl-5H-
[1,2,4]triazino[5,6-b]indole-3-thiol (1) (0.088 g, 0.41 mmol)
according to general procedure E. The crude product was
purified by column chromatography (petroleum ether/EtOAc
2:1) to give a white solid (0.029 g, 18%). 1H NMR (400 MHz,
DMSO-d6) δ 9.93 (s, 1H), 8.34 (d, J = 7.7Hz, 1H), 7.87–7.73
(m, 3H), 7.50 (ddd, J = 7.7, 5.1, 2.4Hz, 2H), 7.40–7.25 (m, 1H),
7.18 (td, J = 7.7, 1.6Hz), 4.35 (s, 2H), 3.81 (s, 3H). 13C NMR
(101 MHz, DMSO-d6) δ 167.33, 166.90, 146.55, 142.14, 141.50,
135.29, 131.47, 129.94, 127.99, 126.66, 125.83, 123.39, 121.93,
117.74, 111.68, 35.28, 27.85. LCMS m/z calc. for C18H15ClN5OS
[M+H]+: 384.2, found 383.8 with tR 2.82min, purity 95%.
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-
3-yl)thio)-N-(2-chlorophenyl)acetamide (39). The
title compound was prepared from 2-bromo-N-(2-
chlorophenyl)acetamide (32) (0.1 g, 0.3387 mmol) and
8-bromo-5-methyl-5H[1,2,4]triazino[5,6-b]indole-3-thiol (2)
(0.083 g, 0.3387 mmol) according to general procedure E.
The crude product was purified by column chromatography
(petroleum ether/EtOAc 2:1) to give a white solid (0.053 g, 35%).
1HNMR (400MHz, DMSO-d6) δ 9.94 (s, 1H), 8.50 (t, J = 2.8Hz,
1H), 7.93 (dt, J = 9.3, 2.7Hz, 1H), 7.88–7.64 (m, 2H), 7.50 (dd, J
= 7.9, 1.6Hz, 1H), 7.28–7.25 (m, 1H), 7.23–7.08 (m, 1H), 4.36 (d,
J = 3.3Hz, 2H), 3.80 (s, 3H). 13C NMR (101 MHz, DMSO-d6)
δ 167.71, 167.22, 146.72, 140.99, 140.61, 135.28, 133.76, 129.96,
127.98, 126.70, 126.29, 125.94, 124.20, 119.69, 115.50, 113.88,
35.45, 28.00. LCMS m/z calc. for C18H13BrClN5OS [M+H]+:
462.7, found 462.7 with tR 3.01min, purity 95%.
2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-
N-(4-(pyridin-2-yloxy)phenyl)acetamide (40). The title
compound was prepared from 5-Methyl-5H-[1,2,4]triazino[5,6-
b]indole-3-thiol (1) (0.030 g, 0.14 mmol), Et3N (1.5 equiv.) and
2-bromo-N-(4-(pyridin-2-yloxy)phenyl)acetamide (33) (0.051 g,
0.17 mmol) according to general procedure E. The reaction
mixture was allowed slowly warm up to room temperature and
stirred overnight and monitored by TLC. The crude product was
purified by column chromatography (petroleum ether/EtOAc
1:1) to give a white solid (39mg, 64%). 1H NMR (400 MHz,
CDCl3) δ 9.87 (s, 1H), 8.46 (dt, J = 1.1, 7.8Hz, 1H), 8.16
(ddd, J = 0.8, 2.1, 5.0Hz, 1H), 7.77 (ddd, J = 1.2, 7.4, 8.5Hz,
1H), 7.68–7.56 (m, 3H), 7.55–7.47 (m, 2H), 7.14–7.04 (m,
2H), 6.96 (ddd, J = 1.0, 5.0, 7.2Hz, 1H), 6.86 (dt, J = 0.9,
8.3Hz, 1H), 4.13 (d, J = 1.5Hz, 2H), 3.87 (s, 3H). 13C NMR
(101 MHz, CDCl3) δ 167.21, 167.08, 150.16, 147.70, 146.55,
142.15, 139.35, 134.91, 131.51, 123.44, 122.66, 121.76, 121.07,
118.33, 117.96, 111.22, 110.16, 35.75, 27.53. LCMS m/z calc. for
C23H19N6O2S [M+H]+: 443.5, found 443.2 with tR 2.78min,
purity> 95%.
N-(4-Chlorophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)propanamide (41). The title compound (41)
was prepared from (34) (Deora et al., 2019) (0.20 g, 0.93 mmol)
and (1) (0.24 g, 0.93 mmol) according to the general procedure
E. The crude product was purified by column chromatography
(petroleum ether/EtOAc 2:1) to give a white solid (0.083 g, 22%).
1H NMR (400 MHz, DMSO-d6) δ 10.61 (s, 1H), 8.30 (d, J =
7.7Hz, 1H), 7.75 (d, J = 5.9Hz, 2H), 7.68 (d, J = 8.6Hz, 2H), 7.47
(ddd, J = 8.0, 6.0, 2.3Hz, 1H), 7.38 (d, J = 8.8Hz, 2H), 4.85 (q,
J = 7.0Hz, 1H), 3.77 (s, 3H), 1.68 (d, J = 7.1Hz, 3H). 13C NMR
(101 MHz, DMSO-d6) δ 170.55, 166.85, 146.49, 142.08, 141.47,
138.40, 131.42, 129.19, 127.53, 123.33, 121.88, 121.25, 117.71,
111.61, 45.12, 27.76, 18.65. LCMS m/z calc. for C19H17ClN5OS+
[M]+: 398.8, found 397.8 with tR 3.03min, purity 95%.
N-(4-Chlorophenyl)-N-methyl-2-((5-methyl-5H-[1,2,4]
triazino[5,6-b]indol-3-yl)thio)acetamide (43). The title
compound was prepared from 2-bromo-N-(4-chlorophenyl)-
N-methylacetamide (36) (0.050 g, 0.19 mmol) and 5-methyl-
5H-[1,2,4]triazino[5,6-b]indole-3-thiol (1) (0.041 g, 0.19 mmol)
according to general procedure E. The crude product was
purified by column chromatography (petroleum ether/EtOAc
1:1) to give a white solid (32.5mg, 28%): 1H NMR (400 MHz,
DMSO-d6) δ 8.32 (d, J = 7.8Hz, 1H), 7.78 (d, J = 4.1Hz, 2H),
7.65–7.35 (m, 5H), 4.05 (d, J = 22.3Hz, 2H), 3.76 (s, 3H), 3.23 (s,
3H). 13C NMR (101 MHz, DMSO-d6) δ 170.55, 166.85, 146.49,
142.08, 141.47, 138.40, 131.42, 129.19, 127.53, 123.33, 121.88,
121.25, 117.71, 111.61, 45.12, 27.76, 18.65. LCMS m/z calc. for
C19H17ClN5OS [M+H]+: 398.2, found 397.8 with tR 3.03min,
purity 95%.
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FIGURE 2 | Chemical structure of hit compound 7 and plans for chemical optimisation.
N-(4-Chlorophenyl)-N-methyl-2-((5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)propanamide (44).
The title compound was prepared from 5-methyl-5H-
[1,2,4]triazino[5,6-b]indole-3-thiol (1) (0.050 g, 0.23 mmol)
and 2-bromo-N-(4-chlorophenyl)acetamide (37) (0.064 g, 0.23
mmol) according to general procedure E. The crude product was
purified by column chromatography (petroleum ether/EtOAc
1:1) to give a gray solid (59mg, 76%). 1H NMR (400 MHz,
DMSO-d6) δ 8.33 (d, J = 7.7Hz, 1H), 7.79 (d, J = 3.8Hz, 2H),
7.69–7.40 (m, 3H), 7.36 (d, J = 8.0Hz, 2H), 4.80 (q, J = 6.9Hz,
1H), 3.70 (s, 3H), 3.20 (s, 3H), 1.51 (d, J = 6.9Hz, 3H). 13C NMR
(101 MHz, DMSO-d6) δ 171.18, 170.94, 166.01, 146.30, 142.40,
142.15, 141.44, 132.85, 131.49, 130.07, 129.96, 123.38, 121.91,
117.69, 111.61, 55.39, 44.54, 37.69, 27.62, 24.57, 22.19, 19.31.
LCMSm/z calc. for C20H20ClN5OS [M+H]+: 412.9, found 412.2
with tR 2.90min, purity> 95%.
N-(4-Chlorophenyl)-2-methyl-2-((5-methyl-5H-[1,2,4]
triazino[5,6-b]indol-3-yl)thio)propanamide (42). 5-Methyl-
5H-[1,2,4]triazino[5,6-b]indole-3-thiol (1) (0.100 g, 0.46 mmol)
was dissolved in anhydrous DMF (15mL) under N2 protection
in an ice bath, followed by addition of NaH 60% dispersion in
mineral oil (0.020 g, 0.51 mmol) in one portion. The mixture
was stirred for 45min with ice bath cooling followed by addition
of 2-bromo-N-(4-chlorophenyl)-2-methylpropanamide (35)
(0.128 g, 0.46 mmol). The mixture was then slowly warmed up
to room temperature and stirred overnight. Once the reaction
was finished, the mixture was poured onto sat. NH4Cl (100mL)
and stirred vigorously for 10min. The resulting suspension was
extracted with EtOAc (30mL × 3). The combined organic layers
were washed with brine, dried over Na2SO4, and concentrated.
The crude product was purified by column chromatography
(petroleum ether/EtOAc 3:1) to give a yellow solid (0.140 g, 74%).
1H NMR (400 MHz, DMSO-d6) δ 9.98 (s, 1H), 8.29 (dt, J = 7.8,
1.0Hz, 1H), 7.85–7.62 (m, 4H), 7.45 (ddd, J = 8.0, 6.7, 1.5Hz,
1H), 7.38–7.17 (m, 2H), 3.73 (s, 3H), 1.81 (s, 6H). 13C NMR
(101 MHz, DMSO-d6) δ 172.39, 166.56, 146.24, 141.98, 141.26,
138.68, 131.44, 128.76, 127.36, 123.33, 122.25, 121.90, 117.71,
111.60, 52.77, 27.78, 26.61. LCMS m/z calc. for C19H16ClN5OS
[M+H]+: 411.9, found 411.9 with tR 2.99min, purity 95%.
RESULTS
Virtual Screening and Hit Identification of
PqsR Inhibitors
In silico virtual screening was performed on the PqsR ligand
binding domain (LBD) crystal structure [PDB: 4JVI; (Ilangovan
et al., 2013)] using the University of Nottingham Managed
Chemical Compound Collection (MCCC) containing 85,061
compounds. Molecular docking was performed using both the
OpenEye docking (OpenEye Scientific Software Inc. (Hawkins
et al., 2007) and Schrödinger Suite for molecular modeling
(Friesner et al., 2004; Halgren et al., 2004). A cut off value of
the docking score function was set to -9.0 and the resulting
high scoring compounds were further examined (Friesner et al.,
2004; Halgren et al., 2004). This gave a library of around 500
diverse molecules that were evaluated using in vitro screening in
a P. aeruginosa PAO1-L mCTX::PPqsA-lux reporter assay (Diggle
et al., 2011).
Compound 7 (Figure 2) with a PAO1-L IC50 of 0.98µM, was
chosen for further optimisation. Disappointingly, this compound
proved inactive when screened against the P. aeruginosa strain
PA14, harboring the mCTX::PPqsA-lux reporter. However, the
hit compound 7 provided a good chemical starting point to
undertake rapid optimisation.
Optimisation of the PqsR Inhibitor Hit
The chemical exploration of 7 initially focused on modifying the
4-chloroanilide, investigating the effect of substitution on the 8-
position of the tricyclic ring and exploration of the effect of the
core linking group substituents (groups R3−5). The compounds
were readily synthesized according to the methods outlined
below (Scheme 1).
The 1,2,4-triazino[5,6-b]indole-3-thiol derivatives (1&2)
(Sharma et al., 2014) were functionalised in two steps
through the alkylation using tert-butyl-2-bromoacetate and
then deprotection to give the carboxylic acids (5–6). These
key intermediates were either reacted with a wide range
of anilines using HATU as the amide coupling agent to
afford compounds (7–28) in high yield. In a complementary
method, intermediates (1&2) were directly alkylated with
2-bromoacetamide intermediates (32–37) (Deora et al., 2019) to
give compounds (38–44) in high over all yield (Scheme 1).
Pharmacological Evaluation and
Structure-Activity Relationship Studies
As shown in Table 1, introduction of a bromine atom to the
8-position of the 5-methyl-5H-[1,2,4]triazino[5,6-b]indole ring
8 maintained biological activity against PAO1-L and showed
comparable activity against PA14. Limited SAR exploration of
the core linking group showed that substitution led to a loss of
biological activity (41–44). SAR exploration of the terminal aryl
group proved more interesting and demonstrated differences
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SCHEME 1 | Synthesis of 2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetamide derivatives. Reagents and conditions: (i) tert-Butyl-2-bromoacetate, NEt3
toluene, 0◦C to rt; (ii) 4M HCl in dioxane, rt; (iii) various anilines, HATU, DMAP, NMP), rt; (iv) NEt3, DCM, 0
◦C to rt.
in biological activity between the unsubstituted and 8-bromo-
substituted 5-methyl-5H-[1,2,4]triazino[5,6-b]indole analogs.
Removing the chlorine atom abolished biological activity (9
and 10), however substitution of the 4-chlorine atom with a
bromine atom 26 maintained biological activity against PAO1-L
and PA14. Disappointingly, removing the bromine atom (R1 =
H) 27 led to a reduction in biological activity against PAO1-L
and inactivity against PA14 (compare 26 and 27). Moving the
chlorine atom from the para- (7 and 8) to the meta-position (11
and 12) resulted in some level of biological activity against the
PAO1-L strain however, 11 and 12 proved inactive against PA14.
The ortho-chloro substituted analogs (38 and 39) were inactive
against both strains and the 3, 4-dichloro analogs only showed
activity in the 8-bromo substituted series (compare 14 vs. 13)
demonstrating divergence of SAR between the 2 series (R1 =
H vs. Br). This surprising SAR was also demonstrated with the
4-fluoro analogs (15 and 16), where only 16 showed biological
activity against the PAO1-L strain, and the 4-methyl analog 17
which was active against the PAO1-L strain (compare 17 vs. 18).
The 4-methoxy (19 and 20) and 4-trifluoromethoxy analogs
(21 and 22) lost activity against both strains. Interestingly, the
addition of a 4-cyanomethyl group 23 gave a compound with
activity against both strains. Introduction of a phenoxy group
24 provided the activity in both strains with almost 2.5-fold
higher in PAO1-L compared to 7, although activity was again
lost in the 8-bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indole
series 25. Introduction of a pyridine-2-yloxy group produced
the most active compound 40 against both PAO1-L and PA14.
Interestingly, increasing the number of heteroatoms on R2 28
led to decreased PqsR inhibition. On the basis that the phenoxy
group of M64 formed a pi-pi stacking interaction with the
side chain of Tyr258 (Kitao et al., 2018) and combined with
docking studies, it is suggested that introducing a 6-membered
heterocycle would lead to enhanced pi-pi stacking with Tyr258
in the PqsR LBD. The resulting pyridine-2-yloxy analog 40
displayed similar activity compared to M64 at PAO1-L and an
enhanced inhibition in PA14 with IC50 values of 0.25 ± 0.12
and 0.34 ± 0.03µM, respectively. The proposed pi-pi stacking
interaction between 40 and Tyr258 was observed by obtaining
the co-crystal structure of 40 in the PqsR LBD (Figure 3).
Crystal Structure of PqsR LBD in Complex
With 40
In order to determine the mode of binding of 40 to PqsR, the co-
crystal structure with the PqsR LBD was obtained at resolution
of 3.2 Å (Figure 3A). The ligand-bound complex reveals that
the tricyclic head group inserts deeply into the hydrophobic
pocket, whilst the thioacetamide linker was positioned in
the outer narrow U-shaped channel. In a similar fashion to
M64, the sulfur atom on the linker allowed 40 to adopt the
required conformation to fit into the binding pocket. The
aromatic tail group points outside this pocket and shows a pi-
pi stacking interaction with Tyr258 with a distance of 4.55 Å.
Interestingly, compared to the reported crystal structure of M64,
compound 40 did not establish a hydrogen bond with Gln194
but instead formed a hydrogen bond with Leu207. In addition,
the pyridinyl side chain of compound 40 had an enhanced
overlap with Tyr258 compared to the phenyl side chain of M64
(Figure 3B), which suggests that 40 could have an enhanced pi-
pi stacking interaction with Tyr258 (see Supplementary Figure 1
and Supplementary Table 1 for further poses and table of
crystallographic properties and refinement).
Impact of PqsR Inhibitors on Pyocyanin
Production
Pyocyanin is an important virulence factor for P. aeruginosa
infections and in particular respiratory and urinary tract
infections. Pyocyanin is a redox-active phenazine the production
of which is regulated via PqsR and PqsE (Hall et al., 2016;
Rampioni et al., 2016; Higgins et al., 2018). Therefore, pyocyanin
production serves as an indirect readout of the activity of the pqs
QS system. In this study, we measured pyocyanin expression in
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TABLE 1 | Pseudomonas aeruginosa PpqsA-lux bioreporter assays of the
compounds synthesized.
Example R1 R2 R3 R4 R5 IC50 (µM) or Remaining
Activity % (RA%) at
10µM (bold)
PAO1-L PA14
7 H 4-Cl H H H 0.98 ± 0.02 NA
8 Br 4-Cl H H H 1.99 ± 0.23 1.60 ± 0.16
9 H H H H H NA NA
10 Br H H H H NA NA
11 H 3-Cl H H H RA% 34 ±
7.3
NA
12 Br 3-Cl H H H RA% 43 ±
20.2
NA
13 H 3,4-dichloro H H H NA NA
14 Br 3,4-dichloro H H H 3.1 ± 0.52 7.58 ± 0.82
15 H 4-F H H H NA NA
16 Br 4-F H H H 1.36 ± 0.21 NA
17 H 4-Me H H H 1.86 ± 0.01 NA
18 Br 4-Me H H H RA% 32 ±
6.2
NA
19 H 4-OMe H H H NA NA
20 Br 4-OMe H H H NA NA
21 H 4-OCF3 H H H RA% 29 ± 6 NA
22 Br 4-OCF3 H H H RA% 23 ± 9 NA
23 H 4-
(cyanomethyl)
H H H 0.62 ± 0.10 2 ± 0.17
24 H 4-phenoxy H H H 0.38 ± 0.06 0.35 ± 0.06
25 Br 4-phenoxy H H H 4.36 ± 0.42 NA
26 H 4-Br H H H 1.71 ± 0.26 1.35 ± 0.19
27 Br 4-Br H H H 23 ± 9 NA
28 H 4-(pyrimidin-
2-yloxy)
H H H 1.04 ± 0.12 1.33 ± 0.33
38 H 2-Cl H H H NA NA
39 Br 2-Cl H H H NA NA
40 H 4-(pyridin-2-
yloxy)
H H H 0.25 ± 0.12 0.34 ± 0.03
41 H 4-Cl Me H H NA NA
42 H 4-Cl H Me Me NA NA
43 H 4-Cl H Me H NA NA
44 H 4-Cl Me H Me NA NA
M64 0.32 ± 0.14 1.22 ± 0.34
Data shown are based on n = 9. NA, not active at 10 M concentration. Bold values
represent percentage of remaining activities at 10 µM concentration.
the presence of the most active pqs inhibitors in this series. The
inhibitors showed a trend consistent with their corresponding
IC50 values in the bioreporter assays. All the compounds showed
inhibition of pyocyanin production of at least 50% compared
with the control when used at a concentration three times higher
than their IC50 (Figure 4). Compound 23 represented the most
potent inhibitor in reducing pyocyanin production particularly
in PA14. Compound 40 reduced pyocyanin production by
over 80% in both strains in agreement with bioreporter
assay results.
Impact of 40 on AQ Production in
Planktonic and Biofilm Cultures
Since PqsR controls expression of the pqsABCDE operon
encoding the enzymes required for different stages of AQ
biosynthesis, quantification of HHQ, and PQS provides a
direct measurement for inhibition of the biosynthetic pathway.
Compound 40 was evaluated for its effect on AQ biosynthesis
at a concentration three times the corresponding IC50 values for
PAO1-L and PA14. Inhibitor 40was found to substantially reduce
the production of HHQ and PQS in planktonic cultures of both
P. aeruginosa strains (Figure 5).
Biofilms are a major challenge in the treatment of chronic P.
aeruginosa infections because of their resilience and protection
of bacteria from environmental stresses such as those posed by
the host immune system and antimicrobial agents (Flemming
et al., 2007; Rybtke et al., 2015). Many genes that are involved
in biofilm formation are directly linked to pqs QS signaling
(Rampioni et al., 2016; Lin et al., 2018). To evaluate the effect
of 40 on AQ signaling in biofilm cultures, PAO1-L was grown
in M9 minimal medium and challenged with either DMSO
control or of 40 (10µM). Following incubation and cell removal,
supernatants were subjected to LC/MS-MS analysis. Figure 5
shows that compound 40 was able to effectively inhibit the
biosynthesis of AQ signals in biofilm cultures (Figure 6).
Effect of 40 on Biofilm Viability
Biofilms are highly recalcitrant to the action of antimicrobials.
Compound M64 has been shown to sensitize biofilms to
antibiotics. To study whether 40 could also impact on
biofilm formation this PqsR inhibitor was administered to
pre-established PAO1-L biofilms (48 h) and their viability
investigated using the LIVE/DEAD R© BacLightTM bacterial
viability kit and confocal laser scanning microscopy (CLSM).
Moreover, to assess whether 40 can act as a non-growth
inhibitory adjuvant to the broad spectrum antibiotic
ciprofloxacin (CIP), combination therapy against mature
PAO1-L biofilms was also tested. PAO1-L biofilms were
established for 2 days before challenging with these treatments
for 6 and 24 h followed by Live/Dead staining. Results showed
that untreated biofilms presented only live bacteria but when
the biofilms were exposed to 40 the growth of the community
increased with respect to untreated controls after both 6 and
24 h (Figure 6). When the biofilms were exposed to CIP, some
evidence of dead bacteria was obtained due to areas of red
staining within the biofilm and, contrary to our hypothesis,
treatment with the quorum sensing inhibitor 40 combined with
CIP did not result in an enhanced biofilm killing (Figure 7) (see
Supplementary Figures 2, 3).
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FIGURE 3 | X-ray crystal structure of PqsR in complex with compound 40 and M64 (PDB:6B8A) (Kitao et al., 2018) (A) X-ray co-crystal structure of 40 bound to
PqsR LBD. The protein structure is presented in gray and residues Tyr258 and Leu207 are labeled in black. (B) Overlapping crystal structures of 40 and M64 in complex
with PqsR ligand binding domain. Compound 40 is represented in yellow and M64 in light blue.
FIGURE 4 | Pyocyanin production by Pseudomonas aeruginosa after
treatment with pqs inhibitors 8, 14, 23, 34, 25, 26, and 40. Quantification of
pyocyanin production after inhibitor treatment at 3 × IC50 for both PAO1-L and
PA14. The graph represents the average of three independent experiments
carried out in triplicate (n = 9).
DISCUSSION
Here, we presented the results of a hit to lead optimisation
process on compound 7 (PAO1-L IC50 0.98 ± 0.02µM, PA14
inactive at 10µM) which was discovered in an initial screening
for PqsR antagonists using a bacterial cell-based reporter assay.
A secondary aim of this work was to improve the potency against
different P. aeruginosa strains. This aspect is of vital importance
in antimicrobial drug discovery as the potency of inhibitors
can vary widely in a strain dependent manner which has a
detrimental downstream effects on their prospective success as
antimicrobial agents (Jackson et al., 2018). In fact, the majority
of published work in relation to PqsR inhibition has only been
validated in a single strain. For this purpose, both PAO1-L and
PA14 were chosen as two of the most studied laboratory strains
FIGURE 5 | Effect of compound 40 on AQ production: Quantification of AQ
concentrations after treatment with the PqsR inhibitor 40 at 3x IC50 value for
PAO1-L and PA14 each strain. The graph represents the average of three
independent experiments carried out in triplicate (n = 9) for both strains.
belonging to the two major P. aeruginosa genomic clusters to
account for any strain differences (Freschi et al., 2015).
To inform the structural variation of 7, crystal structures with
the endogenous ligand [4-hydroxy-2-heptylquinoline (NHQ)]
and the inhibitor M64 were used (Ilangovan et al., 2013;
Kitao et al., 2018). The PqsR LBD is dominated by lipophilic
interactions, therefore the current SAR exploration mainly
focused on varying the aromatic tail substituents and examining
the effect of 8-position substitution. The rationale for these
modifications was primarily based on molecular docking studies
that provided insights into the mode of binding of 7 and
approaches intended to improve potency. The substituent at
the para- position of the aromatic ring appeared to be crucial
for biological activity due to the vital pi-pi stacking interaction
of this group with Tyr258. Compound 40 demonstrated almost
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FIGURE 6 | Quantification of AQ concentrations in PAO1-L biofilm cultures
treated with 40 (10µM). The y axis shows the % of AQs production in relation
to a non-treated DMSO control. Biofilms were grown in M9 minimal medium
for 18 h in 24-well glass bottom plates and supernatants extracted for AQ
analysis.
FIGURE 7 | Bar chart showing PAO1-L biofilm viability quantified after
treatment with different conditions for 6 or 24 h. The concentrations of the
drugs used were ciprofloxacin 60µg/mL (CIP), 40 10µM.
equal sub-micromolar potency in both bioreporter strains in
which a chromosomal transcriptional fusion of PpqsA-lux was
introduced to report on PqsR activation by HHQ and PQS. These
strains emit light upon activation of PqsR by the endogenous
production of these signal molecules. However, upon interaction
with antagonists PqsR is unable to activate the PpqsA promoter
and hence a reduction in bioluminescence is observed (Ilangovan
et al., 2013; Soukarieh et al., 2018a). The results of the SAR in this
assay highlight the importance of testing any prospective anti-
virulence strategy on multiple genetically distinct P. aeruginosa
strains as a means to reduce the chance of failure at both pre-
clinical and clinical stages (Freschi et al., 2015).
However, compounds active in the PpqsA-lux reporter assay
may either be inhibitors of PqsR or of the AQ biosynthetic
enzymes. To confirm PqsR as the potential target for this series,
the co-crystal structure of 40 with PqsR ligand binding domain
was obtained. The crystal structure revealed the binding is
dominated by the pi-pi stacking interaction with Tyr258 and the
hydrogen bonding interaction between the amide linker of 40
and the side chain of Leu207, similar to that previously reported
(Kitao et al., 2018).
To further confirm the inhibition of pqs system, the end
products of this biosynthetic pathway were quantified and the
inhibitory effect of 40 was clearly apparent in the phenotypic
assays. The pqs inhibitor 40 reduced the expression of pyocyanin
substantially at sub-micromolar concentrations and interfered
with the biosynthesis of AQ signals leading to a significant
decrease in their production in both P. aeruginosa genotypes
corroborating the results of the bioreporter assay. Collectively,
these results, along with the co-crystal structure, provide strong
evidence for PqsR as the pqs pathway target of 40 (Zender et al.,
2013; Lu et al., 2014a,b; Starkey et al., 2014). Interestingly, the
inhibitory effect of 40 on AQ production extended beyond the
planktonic growth of P. aeruginosa and was also significant in
biofilm cultures where 40 drastically reduced the AQ levels.
AQ signals and particularly PQS is involved in wide spectrum
of functions including iron acquisition, cytotoxicity, and host
immune response modulation, therefore it is of therapeutic
benefit to reduce or deplete the concentration of these molecule
in P. aeruginosa communities (Hooi et al., 2004; Diggle et al.,
2007; Kim et al., 2010; Lin et al., 2018). Nevertheless, biofilm
treated with 40 showed a slight increase in viability and hence
growth compared to the untreated control contradicting our
hypothesis. The reasons behind this observation were not
investigated but may be due to multiple factors including biofilm
permeability, the presence of efflux pumps or off target effects
(Masi et al., 2017). Compounds with similar scaffolds were
reported previously to act on PqsBC, a β-keto acyl synthase
III enzyme responsible for the condensation of 2-ABA (Maura
et al., 2017). Inhibition of PqsBC leads to the accumulation
of 2-aminoanthranilic acid (2-AA) and 2,4-dihydroxyquinoline
DHQ metabolites that increase P. aeruginosa persistence and
promote chronic infections (Kesarwani et al., 2011; Gruber et al.,
2016). Further investigation is required to ascertain the reasons
behind the inability of 40 to potentiate killing by ciprofloxacin
whilst being a robust inhibitor of PqsR, the production of
alkylquinolones and pyocyanin.
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